A Long-term Extension Study to Evaluate the Safety and Efficacy of APG777 in Patients With Atopic Dermatitis Previously Treated With APG777
Apogee Therapeutics, Inc.
Summary
This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will coincide with the last visit of the Maintenance Period in the Parent Study 2) Extended Treatment Period 3) Post-treatment Follow-up Period. This study will be conducted in participants with atopic dermatitis (AD) who completed the Treatment Period in a prior APG777 study and who, in the opinion of the Investigator, would benefit from long-term treatment with APG777.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Participants who have completed the Treatment Period in a prior APG777 study and were, in the Investigator's opinion, compliant with the study protocol * Participants who, in the Investigator's opinion, would benefit from long-term treatment with APG777 * Use the same non-prescription non-medicated emollient/moisturizer of their choice from the last day of the Parent Study and throughout the LTE study Exclusion Criteria: * Participants who have developed an AE while participating in the Parent Study. which, in the opinion of the Investigator or of the Medical Monitor,…
Interventions
- DrugAPG777
APG777 subcutaneous injection
- DrugAPG777
APG777 subcutaneous injection every 12 weeks
- DrugAPG777
APG777 subcutaneous injection every 24 weeks
Locations (45)
- Investigational SiteFountain Valley, California
- Investigational SiteLos Angeles, California
- Investigational SiteCoral Gables, Florida
- Investigational SiteJacksonville, Florida
- Investigational SiteMargate, Florida
- Investigational SiteDouglasville, Georgia